Creatine has quietly moved from the gym to the pharmacy counter. Customers now arrive asking whether it can help with memory in midlife, muscle loss in older relatives, or joint pain as well as exercise performance. The research has broadened since the 1990s — but so has the marketing, and pharmacy teams need to know what the evidence actually says before recommending a product.
What creatine is and where it sits in UK regulation
Creatine is a nitrogenous organic acid synthesised in the liver, kidneys and pancreas and also obtained from red meat and fish. Endogenous production averages around 1 g per day, with a similar amount from a typical omnivorous diet. Supplemental creatine is sold in the UK as a food supplement, not a medicine, and is therefore regulated under general food law rather than by the Medicines and Healthcare products Regulatory Agency.
The European Food Safety Authority has issued an authorised health claim for creatine: supplementation "increases physical performance in successive bursts of short-term, high-intensity exercise" at a daily intake of 3 g. That is the only claim a UK product is permitted to carry on the label.
The performance evidence — strongest in short, high-intensity work
The International Society of Sports Nutrition's 2021 position stand concluded that creatine monohydrate is "the most effective ergogenic nutritional supplement currently available" for increasing high-intensity exercise capacity and lean body mass during training. Meta-analyses consistently show small but reliable increases in one-repetition maximum strength, jump height and repeated sprint performance in trained and untrained individuals.
Effects on endurance performance are smaller and less consistent. Creatine will not turn a recreational runner into a faster marathoner, and this is worth stating clearly at the counter when a customer has been sold something different by an influencer.
The newer evidence — brain, ageing and recovery
Three areas are driving the current wave of pharmacy interest.
Cognitive function. Several small randomised trials and a 2023 Nature Scientific Reports trial have reported modest benefits of creatine on working memory and processing speed under conditions of sleep deprivation or mental fatigue. A 2024 systematic review concluded the cognitive evidence base is promising but immature; doses used in studies (often 10–20 g/day) are higher than standard exercise protocols.
Sarcopenia and ageing. Combined with resistance training, creatine monohydrate produces modest additional gains in lean mass and grip strength in older adults. NICE's clinical knowledge summary on sarcopenia emphasises resistance exercise and adequate protein; creatine is a reasonable adjunct where training is established, not a substitute for it.
Musculoskeletal pain and recovery. Evidence here is weaker. Creatine may reduce post-exercise muscle damage markers, but studies in osteoarthritis or chronic musculoskeletal pain are small and mixed.
Which form — and why monohydrate still wins
Creatine monohydrate is the form used in the overwhelming majority of published trials. It is also the cheapest by a large margin. Newer salts marketed at a premium — creatine hydrochloride, creatine ethyl ester, buffered creatine (Kre-Alkalyn), magnesium creatine chelate — claim superior absorption or reduced bloating. Head-to-head evidence does not support those claims.
The ISSN position stand is explicit: "creatine monohydrate remains the most extensively studied and clinically effective form of creatine for use in nutritional supplements." Look for products with the Creapure label where possible; it is a German-produced monohydrate used in most clinical trials and is third-party tested for purity.
Dose — loading versus gradual
Two protocols are well established.
| Protocol | Dose | Time to saturation |
|---|---|---|
| Loading | 20 g/day (4 × 5 g) for 5–7 days, then 3–5 g/day | ~1 week |
| Gradual | 3–5 g/day throughout | ~3–4 weeks |
Both reach the same steady-state muscle creatine content. Loading is useful when a specific event is near; gradual dosing is better tolerated and simpler to advise for most customers.
Timing relative to exercise does not meaningfully affect outcomes. Mixing with a carbohydrate- or protein-containing drink modestly increases uptake but is not essential.
Safety, side effects and who to refer
Gastrointestinal discomfort and transient weight gain of 1–2 kg (from intracellular water retention) are the most common effects. The weight gain is not fat and typically plateaus within weeks.
EFSA's safety opinion concluded that long-term use of up to 3 g/day poses no safety concern for healthy adults. Higher doses have been used safely in athletic populations. However, the pharmacy team should refer or advise caution for:
- Customers with known renal impairment, including those on nephrotoxic medicines or diuretics. Creatinine is a metabolite of creatine and supplementation causes a modest, benign rise in serum creatinine; this can be misinterpreted during routine blood tests if the prescriber is not informed.
- Pregnancy and breastfeeding — limited safety data, routine supplementation is not advised.
- Children and adolescents — evidence is limited outside specific clinical conditions; general supplementation is not recommended without specialist input.
- Anyone taking diuretics, where intracellular water shifts may be relevant.
What to say at the counter
A useful framing is: creatine monohydrate, 3–5 g per day, taken daily, is safe and has good evidence for strength work. The evidence for brain and ageing benefits is weaker but growing and requires consistent resistance training to have meaningful effect. Expect a small, non-fat weight gain. Switch to referral if the customer has kidney disease or is pregnant.
Where this fits in UK pharmacy
Sports and wellbeing supplements are an increasingly visible part of the counter conversation. PharmSee's pharmacy directory shows the community pharmacy network patients rely on for this kind of evidence-based advice; our pharmacist jobs listings reflect growing demand for clinical pharmacists confident in supplement counselling alongside medicine advice.
Caveats
The literature summarised above draws on EFSA's 2011 safety opinion, NICE CKS sarcopenia guidance, the 2021 ISSN position stand and a selection of recent systematic reviews. Individual response to creatine varies, and a small minority of customers are "non-responders" whose muscle creatine content is already near saturation. As always, anything that changes a medicine regimen or an existing renal, cardiac or hepatic diagnosis should route through the patient's prescriber.